May. 20 at 3:12 PM
$DARE
The post-earnings reaction looks largely sentiment-driven.
On fundamentals, the update wasn’t weak: earnings beat expectations, guidance remained solid, product rollout roadmap is clear, and clinical progress along with funding updates continues to advance.
Yet the market reacted by compressing valuation first, leading to an oversold move.
Is
$DARE a mispricing setup for recovery, or the start of a broader re-rating phase?
